» Articles » PMID: 16306861

Differences in CYP3A5*3 Genotype Distribution and Combinations with Other Polymorphisms Between Spaniards and Other Caucasian Populations

Overview
Journal Ther Drug Monit
Specialty Pharmacology
Date 2005 Nov 25
PMID 16306861
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The goal of this study was to detect genotypic differences between Spaniards and other related populations regarding CYP3A4*1B, CYP3A5*3, and ABCB1 (MDR1) C3435T polymorphisms. DNA from 177 Spanish patients were analyzed for the presence of these mutations using PCR-restriction fragment length polymorphism or direct sequencing. The observed frequencies for CYP3A4*1B, CYP3A5*3, and C3435T alleles were within normal values in Caucasians (0.04, 0.91, and 0.5, respectively). However, 2.8% of the patients were homozygous for the wild-type CYP3A5*1 allele, an extremely uncommon genotype in other Caucasians. In addition, analysis of CYP3A4-3A5 haplotypes revealed the existence of 2 unusual subgroups: patients who were homozygous wild-type for both polymorphisms, and patients showing a CYP3A4*1A/*1B-CYP3A5*3/*3 genotype combination. The incidence of CYP3A5*1/*1 carriers and the occurrence of subjects combining the 2 above-mentioned unusual genotype combinations were more frequent in Spanish-Caucasians compared with American- or European-Caucasians. ABCB1 C3435T genotype frequencies were equally distributed between both single and combined CYP3A4 and 3A5 genotypes. These findings suggest that dose requirements for drugs metabolized by CYP3A and certain allele-disease association studies in white populations could show discrepancies in Spaniards.

Citing Articles

Ethnicity-based classifications and medical genetics: One Health approaches from a Western Pacific perspective.

Edinur H, Mat-Ghani S, Chambers G Front Genet. 2022; 13:970549.

PMID: 36147511 PMC: 9485872. DOI: 10.3389/fgene.2022.970549.


Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients.

Pinon M, De Nicolo A, Pizzol A, Antonucci M, DAvolio A, Serpe L Sci Rep. 2021; 11(1):443.

PMID: 33432012 PMC: 7801660. DOI: 10.1038/s41598-020-79574-7.


Failure of Achieving Tacrolimus Target Blood Concentration Might Be Avoided by a Wide Genotyping of Transplanted Patients: Evidence from a Retrospective Study.

Pallio G, Irrera N, Bitto A, Mannino F, Minutoli L, Rottura M J Pers Med. 2020; 10(2).

PMID: 32492825 PMC: 7354451. DOI: 10.3390/jpm10020047.


High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor.

Barreda-Sanchez M, Buendia-Martinez J, Glover-Lopez G, Carazo-Diaz C, Ballesta-Martinez M, Lopez-Gonzalez V Orphanet J Rare Dis. 2019; 14(1):59.

PMID: 30808393 PMC: 6390611. DOI: 10.1186/s13023-019-1031-7.


CYP3A genotypes of donors but not those of the patients increase the risk of acute rejection in renal transplant recipients on calcineurin inhibitors: a pilot study.

Gervasini G, Garcia-Pino G, Vergara E, Mota-Zamorano S, Garcia-Cerrada M, Luna E Eur J Clin Pharmacol. 2017; 74(1):53-60.

PMID: 29043387 DOI: 10.1007/s00228-017-2353-9.